Community-Based Outreach for People Living With Methamphetamine-Associated Cardiomyopathy

Overview

Journal JACC Case Rep

Specialty Cardiology & Vascular Diseases

Date 2024 Nov 1

PMID 39484319

Authors

Joey Chiang

Jaimie Pechan

Kate Smith

Cooper B Kersey

Mrinal Yadava

Sarah Leyde

Danelle Hidano

Affiliations

Soon will be listed here.

Abstract

Methamphetamine-associated cardiomyopathy continues to grow within the United States. Although initiation of guideline-directed medical therapy and cessation of methamphetamine are cornerstones of therapy, many barriers to guideline-directed medical therapy use exist for patients with methamphetamine-associated cardiomyopathy. This paper presents a case series of patients who demonstrated profound clinical and echocardiographic improvement with engagement in a community heart failure program paired with the use of alarmed pill containers to target medication adherence.

References

Dickson S, Thomas I, Bhatia H, Nishimura M, Mahmud E, Tu X . Methamphetamine-Associated Heart Failure Hospitalizations Across the United States: Geographic and Social Disparities. J Am Heart Assoc. 2021; 10(16):e018370. PMC: 8475042. DOI: 10.1161/JAHA.120.018370. View

Schurer S, Klingel K, Sandri M, Majunke N, Besler C, Kandolf R . Clinical Characteristics, Histopathological Features, and Clinical Outcome of Methamphetamine-Associated Cardiomyopathy. JACC Heart Fail. 2017; 5(6):435-445. DOI: 10.1016/j.jchf.2017.02.017. View

Hale T, Jethwani K, Kandola M, Saldana F, Kvedar J . A Remote Medication Monitoring System for Chronic Heart Failure Patients to Reduce Readmissions: A Two-Arm Randomized Pilot Study. J Med Internet Res. 2016; 18(5):e91. PMC: 4890732. DOI: 10.2196/jmir.5256. View

Reddy P, Ng T, Oh E, Moady G, Elkayam U . Clinical Characteristics and Management of Methamphetamine-Associated Cardiomyopathy: State-of-the-Art Review. J Am Heart Assoc. 2020; 9(11):e016704. PMC: 7428977. DOI: 10.1161/JAHA.120.016704. View

Hersi M, Corace K, Hamel C, Esmaeilisaraji L, Rice D, Dryburgh N . Psychosocial and pharmacologic interventions for problematic methamphetamine use: Findings from a scoping review of the literature. PLoS One. 2023; 18(10):e0292745. PMC: 10566716. DOI: 10.1371/journal.pone.0292745. View

Voskoboinik A, Ihle J, Bloom J, Kaye D . Methamphetamine-associated cardiomyopathy: patterns and predictors of recovery. Intern Med J. 2016; 46(6):723-7. DOI: 10.1111/imj.13050. View

Bhatia H, Nishimura M, Dickson S, Adler E, Greenberg B, Thomas I . Clinical and echocardiographic outcomes in heart failure associated with methamphetamine use and cessation. Heart. 2020; 107(9):741-747. PMC: 8842989. DOI: 10.1136/heartjnl-2020-317635. View

Zhao S, Seng S, Deluna A, Yu E, Crawford M . Comparison of Clinical Characteristics and Outcomes of Patients With Reversible Versus Persistent Methamphetamine-Associated Cardiomyopathy. Am J Cardiol. 2019; 125(1):127-134. DOI: 10.1016/j.amjcard.2019.09.030. View

Manja V, Sandhu A, Asch S, Frayne S, McGovern M, Chen C . Healthcare utilization and left ventricular ejection fraction distribution in methamphetamine use associated heart failure hospitalizations. Am Heart J. 2024; 270:156-160. DOI: 10.1016/j.ahj.2023.12.014. View

10.

Manja V, Nrusimha A, Gao Y, Sheikh A, McGovern M, Heidenreich P . Methamphetamine-associated heart failure: a systematic review of observational studies. Heart. 2022; 109(3):168-177. DOI: 10.1136/heartjnl-2022-321610. View

11.

Al-Yafeai Z, Ali S, Brown J, Venkataraj M, Bhuiyan M, Mosa Faisal A . Cardiomyopathy-Associated Hospital Admissions Among Methamphetamine Users: Geographical and Social Disparities. JACC Adv. 2024; 3(7):100840. PMC: 11312042. DOI: 10.1016/j.jacadv.2024.100840. View